|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000083307 |
Summary for GRHL2 |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000083307 | Gene symbol | GRHL2 |
| Gene name | grainyhead like transcription factor 2 | |
| HGNC | 2799 | |
| Entrez ID | 79977 | |
| Gene type | protein_coding | |
| Synonyms | GRHL2|FLJ13782|BOM | |
| UniProtAcc | Q6ISB3 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for GRHL2 |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor male and normal male samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| GRHL2 | 4.09e+03 | 1.28e+00 | 3.72e-01 | 3.43e+00 | 5.94e-04 | 2.10e-03 | BLCA |
| GRHL2 | 1.18e+03 | 3.78e+00 | 6.63e-01 | 5.70e+00 | 1.19e-08 | 1.33e-07 | CHOL |
| Differentially expressed gene analysis between tumor female and normal female samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| GRHL2 | 2.16e+03 | 1.19e+00 | 1.99e-01 | 5.99e+00 | 2.12e-09 | 4.03e-08 | READ |
Top |
Sex-biased somatic mutation for GRHL2 |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for GRHL2 |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| SARC | cg03650674 | chr8:101493758 | CGI:chr8:101493284-101494202 | promoter,gene body | 4.96e-01 | 3.42e-01 | 3.43e+00 | 6.15e-04 | 2.37e-03 | 1.53e-01 |
| SARC | cg18004756 | chr8:101492254 | CGI:chr8:101492250-101492542 | promoter | 6.34e-01 | 5.04e-01 | 3.44e+00 | 5.75e-04 | 2.25e-03 | 1.30e-01 |
| SARC | cg25330243 | chr8:101492273 | CGI:chr8:101492250-101492542 | promoter | 4.92e-01 | 3.28e-01 | 3.59e+00 | 3.25e-04 | 1.41e-03 | 1.64e-01 |
| SARC | cg16435779 | chr8:101492219 | CGI:chr8:101492250-101492542 | promoter | 6.24e-01 | 4.91e-01 | 4.30e+00 | 1.69e-05 | 1.02e-04 | 1.33e-01 |
| SARC | cg11397370 | chr8:101492251 | CGI:chr8:101492250-101492542 | promoter | 5.30e-01 | 4.29e-01 | 3.96e+00 | 7.52e-05 | 3.98e-04 | 1.01e-01 |
| SARC | cg03780851 | chr8:101492336 | CGI:chr8:101492250-101492542 | promoter | 6.01e-01 | 4.82e-01 | 4.00e+00 | 6.29e-05 | 3.40e-04 | 1.19e-01 |
| SARC | cg25639415 | chr8:101492393 | CGI:chr8:101492250-101492542 | promoter | 5.86e-01 | 4.76e-01 | 3.47e+00 | 5.25e-04 | 2.09e-03 | 1.10e-01 |
| SARC | cg20574490 | chr8:101492438 | CGI:chr8:101492250-101492542 | UTR,promoter,exon,gene body | 6.68e-01 | 5.47e-01 | 4.64e+00 | 3.57e-06 | 2.37e-05 | 1.21e-01 |
| LAML | cg17885542 | chr8:101491716 | CGI:chr8:101492250-101492542 | promoter | 4.29e-01 | 5.39e-01 | -2.62e+00 | 8.79e-03 | 1.98e-02 | -1.09e-01 |
| LAML | cg20342184 | chr8:101491742 | CGI:chr8:101492250-101492542 | promoter | 2.32e-01 | 3.41e-01 | -3.31e+00 | 9.36e-04 | 2.84e-03 | -1.09e-01 |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| KIRC | cg18004756 | chr8:101492254 | CGI:chr8:101492250-101492542 | promoter | 1.18e-01 | 1.75e-02 | 6.38e+00 | 1.78e-10 | 3.73e-09 | 1.01e-01 |
| KIRC | cg16688483 | chr8:101494161 | CGI:chr8:101493284-101494202 | promoter,gene body | 2.88e-01 | 1.63e-01 | 4.03e+00 | 5.51e-05 | 1.21e-04 | 1.25e-01 |
| LUSC | cg10899768 | chr8:101494407 | CGI:chr8:101493284-101494202 | promoter,gene body | 1.62e-01 | 3.13e-01 | -3.62e+00 | 2.98e-04 | 1.21e-03 | -1.51e-01 |
| LUSC | cg01519063 | chr8:101493065 | CGI:chr8:101493284-101494202 | promoter,gene body | 2.34e-01 | 3.82e-01 | -3.77e+00 | 1.64e-04 | 8.77e-04 | -1.48e-01 |
| LUSC | cg18899777 | chr8:101494323 | CGI:chr8:101493284-101494202 | promoter,gene body | 1.90e-01 | 3.17e-01 | -3.70e+00 | 2.18e-04 | 1.02e-03 | -1.27e-01 |
| COAD | cg10899768 | chr8:101494407 | CGI:chr8:101493284-101494202 | promoter,gene body | 1.93e-01 | 3.53e-01 | -4.62e+00 | 3.87e-06 | 2.94e-05 | -1.60e-01 |
| COAD | cg14202477 | chr8:101492631 | CGI:chr8:101492250-101492542 | UTR,promoter,exon,gene body | 2.17e-01 | 3.29e-01 | -4.35e+00 | 1.38e-05 | 7.52e-05 | -1.12e-01 |
| COAD | cg01519063 | chr8:101493065 | CGI:chr8:101493284-101494202 | promoter,gene body | 2.14e-01 | 3.56e-01 | -4.39e+00 | 1.14e-05 | 6.49e-05 | -1.42e-01 |
| COAD | cg08988797 | chr8:101493285 | CGI:chr8:101493284-101494202 | promoter,gene body | 1.09e-01 | 2.42e-01 | -4.39e+00 | 1.14e-05 | 6.49e-05 | -1.32e-01 |
| COAD | cg18899777 | chr8:101494323 | CGI:chr8:101493284-101494202 | promoter,gene body | 2.09e-01 | 3.65e-01 | -4.66e+00 | 3.15e-06 | 2.55e-05 | -1.56e-01 |
| LIHC | cg14202477 | chr8:101492631 | CGI:chr8:101492250-101492542 | UTR,promoter,exon,gene body | 5.96e-01 | 4.84e-01 | 3.55e+00 | 3.88e-04 | 6.84e-04 | 1.12e-01 |
| LIHC | cg01519063 | chr8:101493065 | CGI:chr8:101493284-101494202 | promoter,gene body | 7.49e-01 | 6.15e-01 | 4.33e+00 | 1.46e-05 | 3.81e-05 | 1.33e-01 |
| KIRP | cg14202477 | chr8:101492631 | CGI:chr8:101492250-101492542 | UTR,promoter,exon,gene body | 4.75e-01 | 3.61e-01 | 2.77e+00 | 5.55e-03 | 7.79e-03 | 1.14e-01 |
| CHOL | cg23973429 | chr8:101492518 | CGI:chr8:101492250-101492542 | UTR,promoter,exon,gene body | 1.29e-01 | 2.60e-01 | -3.02e+00 | 2.51e-03 | 1.19e-02 | -1.31e-01 |
| CHOL | cg03023152 | chr8:101493328 | CGI:chr8:101493284-101494202 | promoter,gene body | 9.67e-02 | 2.19e-01 | -3.32e+00 | 9.08e-04 | 1.01e-02 | -1.23e-01 |
| CHOL | cg10899768 | chr8:101494407 | CGI:chr8:101493284-101494202 | promoter,gene body | 2.49e-01 | 5.73e-01 | -2.95e+00 | 3.19e-03 | 1.32e-02 | -3.24e-01 |
| CHOL | cg14202477 | chr8:101492631 | CGI:chr8:101492250-101492542 | UTR,promoter,exon,gene body | 2.89e-01 | 4.82e-01 | -2.80e+00 | 5.09e-03 | 1.63e-02 | -1.93e-01 |
| CHOL | cg01519063 | chr8:101493065 | CGI:chr8:101493284-101494202 | promoter,gene body | 2.63e-01 | 6.31e-01 | -3.54e+00 | 4.02e-04 | 8.32e-03 | -3.67e-01 |
| CHOL | cg08988797 | chr8:101493285 | CGI:chr8:101493284-101494202 | promoter,gene body | 1.80e-01 | 2.86e-01 | -2.06e+00 | 3.90e-02 | 4.26e-02 | -1.06e-01 |
| CHOL | cg18899777 | chr8:101494323 | CGI:chr8:101493284-101494202 | promoter,gene body | 2.93e-01 | 5.42e-01 | -2.65e+00 | 7.96e-03 | 1.92e-02 | -2.49e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg03023152 | chr8:101493328 | CGI:chr8:101493284-101494202 | promoter,gene body | 1.05e-01 | 2.27e-01 | -1.23e+01 | 7.90e-35 | 2.26e-33 | -1.21e-01 |
| BRCA | cg10899768 | chr8:101494407 | CGI:chr8:101493284-101494202 | promoter,gene body | 2.13e-01 | 4.43e-01 | -1.31e+01 | 2.54e-39 | 1.68e-37 | -2.30e-01 |
| BRCA | cg05458052 | chr8:101491664 | CGI:chr8:101492250-101492542 | promoter | 1.07e-01 | 2.79e-01 | -1.31e+01 | 3.69e-39 | 2.36e-37 | -1.72e-01 |
| BRCA | cg17885542 | chr8:101491716 | CGI:chr8:101492250-101492542 | promoter | 1.45e-01 | 3.00e-01 | -1.28e+01 | 1.41e-37 | 6.55e-36 | -1.55e-01 |
| BRCA | cg20342184 | chr8:101491742 | CGI:chr8:101492250-101492542 | promoter | 1.23e-01 | 2.83e-01 | -1.34e+01 | 8.29e-41 | 7.96e-39 | -1.60e-01 |
| BRCA | cg14202477 | chr8:101492631 | CGI:chr8:101492250-101492542 | UTR,promoter,exon,gene body | 2.46e-01 | 4.49e-01 | -1.28e+01 | 1.48e-37 | 6.85e-36 | -2.03e-01 |
| BRCA | cg01519063 | chr8:101493065 | CGI:chr8:101493284-101494202 | promoter,gene body | 2.42e-01 | 4.95e-01 | -1.36e+01 | 4.80e-42 | 6.44e-40 | -2.53e-01 |
| BRCA | cg08988797 | chr8:101493285 | CGI:chr8:101493284-101494202 | promoter,gene body | 1.11e-01 | 2.50e-01 | -1.25e+01 | 9.88e-36 | 3.27e-34 | -1.39e-01 |
| BRCA | cg18899777 | chr8:101494323 | CGI:chr8:101493284-101494202 | promoter,gene body | 2.47e-01 | 4.80e-01 | -1.35e+01 | 2.76e-41 | 3.00e-39 | -2.33e-01 |
| LUAD | cg10899768 | chr8:101494407 | CGI:chr8:101493284-101494202 | promoter,gene body | 2.03e-01 | 3.18e-01 | -3.10e+00 | 1.97e-03 | 5.04e-03 | -1.15e-01 |
| LUAD | cg18899777 | chr8:101494323 | CGI:chr8:101493284-101494202 | promoter,gene body | 2.15e-01 | 3.48e-01 | -3.96e+00 | 7.45e-05 | 7.73e-04 | -1.34e-01 |
| LIHC | cg05458052 | chr8:101491664 | CGI:chr8:101492250-101492542 | promoter | 2.92e-01 | 1.33e-01 | 2.36e+00 | 1.83e-02 | 2.25e-02 | 1.59e-01 |
| KIRP | cg03650674 | chr8:101493758 | CGI:chr8:101493284-101494202 | promoter,gene body | 1.99e-01 | 5.51e-02 | 2.44e+00 | 1.48e-02 | 2.18e-02 | 1.44e-01 |
| KIRP | cg18004756 | chr8:101492254 | CGI:chr8:101492250-101492542 | promoter | 1.85e-01 | 5.24e-02 | 2.94e+00 | 3.24e-03 | 8.06e-03 | 1.32e-01 |
| KIRP | cg25330243 | chr8:101492273 | CGI:chr8:101492250-101492542 | promoter | 1.86e-01 | 4.23e-02 | 3.02e+00 | 2.50e-03 | 6.82e-03 | 1.43e-01 |
| KIRP | cg16435779 | chr8:101492219 | CGI:chr8:101492250-101492542 | promoter | 1.99e-01 | 6.55e-02 | 2.11e+00 | 3.53e-02 | 3.93e-02 | 1.34e-01 |
| KIRP | cg11397370 | chr8:101492251 | CGI:chr8:101492250-101492542 | promoter | 2.50e-01 | 1.46e-01 | 2.33e+00 | 2.00e-02 | 2.67e-02 | 1.04e-01 |
| KIRP | cg03780851 | chr8:101492336 | CGI:chr8:101492250-101492542 | promoter | 2.56e-01 | 1.05e-01 | 2.01e+00 | 4.44e-02 | 4.60e-02 | 1.50e-01 |
Top |
Exon skipping events with PSI in TCGA for GRHL2 |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Landscape of exon skipping events across multiple cancer types. |
 |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for GRHL2 |
| ∗Please access CAeditome for RNA editing annotation. |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for GRHL2 |
| TFs related to GRHL2. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| LGG | ZNF235 | GRHL2 | 4.63e+00 | 9.84e-01 | 4.16e+00 | 1.02e-02 | Male-biased |
| READ | DUX4 | GRHL2 | 3.92e+00 | 6.42e-03 | 4.86e+00 | 9.90e-01 | Female-biased |
| READ | DUXA | GRHL2 | 3.88e+00 | 1.30e-02 | 4.64e+00 | 9.81e-01 | Female-biased |
| READ | MIXL1 | GRHL2 | 4.04e+00 | 6.82e-03 | 4.97e+00 | 9.90e-01 | Female-biased |
| READ | POU2F2 | GRHL2 | 3.26e+00 | 1.77e-03 | 4.55e+00 | 9.92e-01 | Female-biased |
| READ | POU3F3 | GRHL2 | 2.95e+00 | 5.27e-04 | 4.61e+00 | 9.93e-01 | Female-biased |
| READ | POU4F2 | GRHL2 | 3.13e+00 | 1.87e-03 | 4.40e+00 | 9.89e-01 | Female-biased |
| READ | POU5F1B | GRHL2 | 3.38e+00 | 3.24e-03 | 4.51e+00 | 9.90e-01 | Female-biased |
| READ | SOX17 | GRHL2 | 3.31e+00 | 7.15e-03 | 4.21e+00 | 9.81e-01 | Female-biased |
| READ | SOX6 | GRHL2 | 3.34e+00 | 4.38e-03 | 4.38e+00 | 9.87e-01 | Female-biased |
| READ | STAT2 | GRHL2 | 2.31e+00 | 4.90e-04 | 3.97e+00 | 9.82e-01 | Female-biased |
| READ | YY1 | GRHL2 | 3.32e+00 | 6.95e-03 | 4.23e+00 | 9.81e-01 | Female-biased |
| READ | ZKSCAN2 | GRHL2 | 3.15e+00 | 9.21e-04 | 4.63e+00 | 9.93e-01 | Female-biased |
| READ | ZNF25 | GRHL2 | 2.64e+00 | 5.15e-04 | 4.29e+00 | 9.89e-01 | Female-biased |
| READ | ZNF334 | GRHL2 | 2.67e+00 | 1.45e-04 | 4.73e+00 | 9.95e-01 | Female-biased |
| READ | ZNF570 | GRHL2 | 2.33e+00 | 2.46e-04 | 4.21e+00 | 9.88e-01 | Female-biased |
| READ | ZNF620 | GRHL2 | 3.10e+00 | 4.62e-03 | 4.12e+00 | 9.81e-01 | Female-biased |
| READ | ZNF713 | GRHL2 | 3.39e+00 | 5.79e-03 | 4.35e+00 | 9.85e-01 | Female-biased |
| READ | ZNF74 | GRHL2 | 3.49e+00 | 8.32e-03 | 4.36e+00 | 9.82e-01 | Female-biased |
| READ | ZNF79 | GRHL2 | 2.44e+00 | 1.05e-04 | 4.60e+00 | 9.94e-01 | Female-biased |
| THYM | POU3F3 | GRHL2 | 3.23e+00 | 3.61e-03 | 4.16e+00 | 9.83e-01 | Female-biased |
| THYM | POU5F1B | GRHL2 | 3.76e+00 | 9.66e-03 | 4.46e+00 | 9.82e-01 | Female-biased |
| THYM | ZKSCAN2 | GRHL2 | 3.45e+00 | 6.88e-03 | 4.22e+00 | 9.81e-01 | Female-biased |
| THYM | ZNF25 | GRHL2 | 3.10e+00 | 2.65e-03 | 4.11e+00 | 9.83e-01 | Female-biased |
| THYM | ZNF334 | GRHL2 | 2.85e+00 | 9.72e-04 | 4.11e+00 | 9.85e-01 | Female-biased |
| THYM | ZNF79 | GRHL2 | 2.75e+00 | 1.15e-03 | 3.96e+00 | 9.81e-01 | Female-biased |
| GRHL2 related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
 |
Top |
Sex-biased RBP-ES network for GRHL2 |
| RBPs related to ES in GRHL2. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| LUAD | HNRNPA1L2 | exon_skip_485250 | 9.08e+00 | 9.86e-01 | 8.75e+00 | 9.93e-03 | Male-biased |
| GRHL2 related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
| ENSG00000083307 | SNHG4,hsa-mir-665,GRHL2 | Male-specific ceRNA | TCGA-BLCA |
| ENSG00000083307 | AC026362.1,hsa-mir-665,GRHL2 | Male-specific ceRNA | TCGA-BLCA |
| ENSG00000083307 | OGFRP1,hsa-mir-665,GRHL2 | Male-specific ceRNA | TCGA-BLCA |
| ENSG00000083307 | LINC01018,hsa-mir-122,GRHL2 | Tumor-specific sex-biased ceRNA | TCGA-KIRP |
| ENSG00000083307 | GPR176-DT,hsa-mir-665,GRHL2 | Male-specific ceRNA | TCGA-KIRP |
| ENSG00000083307 | LINC01783,hsa-mir-665,GRHL2 | Male-specific ceRNA | TCGA-KIRP |
| ENSG00000083307 | BX284668.2,hsa-mir-665,GRHL2 | Male-specific ceRNA | TCGA-KIRP |
| ENSG00000083307 | Z95331.1,hsa-mir-665,GRHL2 | Male-specific ceRNA | TCGA-KIRP |
| ENSG00000083307 | NPHP3-AS1,hsa-mir-665,GRHL2 | Male-specific ceRNA | TCGA-KIRP |
| ENSG00000083307 | GRASLND,hsa-mir-665,GRHL2 | Male-specific ceRNA | TCGA-KIRP |
| ENSG00000083307 | HAGLR,hsa-mir-665,GRHL2 | Male-specific ceRNA | TCGA-KIRP |
| ENSG00000083307 | AC106795.2,hsa-mir-665,GRHL2 | Male-specific ceRNA | TCGA-KIRP |
| ENSG00000083307 | AL157832.1,hsa-mir-665,GRHL2 | Male-specific ceRNA | TCGA-KIRP |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs7017753 | chr8:97847209:T:C | - | 0.0409393185746122 | 0.0111617074260786 | LUAD | Female-baised eQTL |
| rs2515219 | chr8:98811822:G:A | - | 0.0730044306947202 | 0.0415349982113688 | COAD | Female-baised eQTL |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs73701931 | chr8:101573038:C:G | gene | 0.120415251552798 | 0.0252607993194232 | COAD | Male-baised eQTL |
| rs73701932 | chr8:101574903:T:C | gene | 0.115065832250708 | 0.0265508066739517 | COAD | Male-baised eQTL |
| rs11996495 | chr8:101565555:T:A | gene | 0.106696314425056 | 0.0290577442802998 | COAD | Male-baised eQTL |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
 | Gene ID: ENSG00000083307 |
| CpG Site: cg14686437 | |
| Position to Gene: gene,enhancer | |
| Male Effect: - | |
| Female Effect: -0.394991055936746 |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg14686437 | chr8:101495609 | gene,enhancer | -0.394991055936746 | 4.23964797754711e-12 | -0.4721564435939093 | 2.7622996496732996e-15 | LUAD |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of GRHL2 |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
| ENSG00000083307 | GRHL2 | C1837640 | Deafness, Autosomal Dominant 28 | 1 | CTD_human |
| ENSG00000083307 | GRHL2 | C4014987 | Nail and tooth abnormalities, marginal palmoplantar keratoderma, oral hyperpigmentation syndrome | 1 | CTD_human |
